# Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

> **NCT04356495** · PHASE2,PHASE3 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 412 (actual)

## Conditions studied

- Corona Virus Infection
- Sars-CoV2

## Interventions

- **DIETARY_SUPPLEMENT:** Vitamins
- **DRUG:** Telmisartan
- **DRUG:** Ciclesonide
- **DRUG:** interferon β-1b

## Key facts

- **NCT ID:** NCT04356495
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-22
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2026-05-12

## Collaborators

- University of Bordeaux

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356495, "Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04356495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*